Jazz Pharmaceuticals Reveals Stellar Financial Performance and 2026 Guidance#Jazz_Pharmaceuticals#HER2-targeted_therapy#Pipeline_Products
Jazz Pharmaceuticals Reveals Stellar Financial Performance and 2026 Guidance
Jazz Pharmaceuticals announces impressive 2025 financial results, showing significant revenue growth and projects a strong forecast for 2026, led by key product launches.
third-news.com
February 24, 2026 at 9:17 PM
Jazz Pharmaceuticals Reveals Stellar Financial Performance and 2026 Guidance#Jazz_Pharmaceuticals#HER2-targeted_therapy#Pipeline_Products
Tagworks Pharmaceuticals Initiates Clinical Trials for TGW211, a New HER2-Targeted Radioimmunoconjugate#Netherlands#Nijmegen#HER2-targeted_therapy#Tagworks_Pharmaceuticals#TGW211
Tagworks Pharmaceuticals Initiates Clinical Trials for TGW211, a New HER2-Targeted Radioimmunoconjugate
Tagworks Pharmaceuticals has announced the start of a Phase 0/1 clinical trial for TGW211, a radioimmunoconjugate targeting HER2-positive tumors. This study marks a significant milestone for the company.
third-news.com
October 16, 2025 at 3:52 PM
Tagworks Pharmaceuticals Initiates Clinical Trials for TGW211, a New HER2-Targeted Radioimmunoconjugate#Netherlands#Nijmegen#HER2-targeted_therapy#Tagworks_Pharmaceuticals#TGW211
Lunit AI Revolutionizes HER2-Targeted Therapies in Colorectal Cancer Patient Predictions#South_Korea#Seoul#Lunit#AI-powered_solutions#HER2-targeted_therapy
Lunit AI Revolutionizes HER2-Targeted Therapies in Colorectal Cancer Patient Predictions
Recent findings highlight how Lunit's AI tools can accurately predict outcomes for HER2-targeted therapies in metastatic colorectal cancer, transforming patient care.
third-news.com
January 23, 2025 at 2:21 PM
Lunit AI Revolutionizes HER2-Targeted Therapies in Colorectal Cancer Patient Predictions#South_Korea#Seoul#Lunit#AI-powered_solutions#HER2-targeted_therapy